The impact of adjuvant vinorelbine (VIN) and cisplatin (CIS) on quality of life (QoL): Results from The National Cancer Institute of Canada Clinical Trials Group Trial BR.10 randomized trial of VIN/CIS versus observation in stage IB and II non-small cell lung cancer (NSCLC)